Biocause Pharma(000627)2024-10-14 10:28Financial Performance - The estimated net profit for the first three quarters of 2024 is a loss of -212.9954 million yuan, compared to a loss of -20.9636 million yuan after deducting non-recurring gains and losses[2] - In Q3 2024, the estimated net profit is expected to be between 20 million yuan and 50 million yuan, compared to a loss of -25.5987 million yuan in the same period last year[2] - The company reported a narrowing of losses in the first three quarters of 2024 compared to the first half of the year due to improved investment income[4] - The financial data presented is preliminary and has not been audited by the accounting firm[3] Insurance Premiums - The original insurance premium income for the first three quarters of 2024 reached 30.342 billion yuan[4] - The company aims to maintain a stable premium income while adjusting business pace and structure according to market conditions[4] Business Strategy - The company has been optimizing its product structure and enhancing new business value to mitigate the impact of increased reserve provisions due to declining bond yields[4] - The company is focusing on the development of long-term value and risk protection business[4] - The company is committed to enhancing its operational capabilities through improved management systems and talent reserves[4] Future Disclosures - The company plans to provide detailed disclosures regarding its operational performance in the Q3 2024 report[5]